Bayer CV Pact Gives AI-Focused Sensyne Health Its First Big Deal Since 2018 IPO
Executive Summary
The UK-based group will help Bayer accelerate clinical development of new treatments for cardiovascular disease using Sensyne Health’s clinical AI technology platform and NHS data.